| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
An official ATS statement: hepatotoxicity of antituberculosis therapy.
|
Am J Respir Crit Care Med
|
2006
|
5.02
|
|
2
|
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
|
PLoS Med
|
2007
|
2.86
|
|
3
|
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
|
Am J Respir Crit Care Med
|
2003
|
2.56
|
|
4
|
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
|
Am J Respir Crit Care Med
|
2004
|
2.40
|
|
5
|
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
|
Clin Infect Dis
|
2009
|
2.36
|
|
6
|
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
|
Clin Infect Dis
|
2005
|
2.34
|
|
7
|
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
|
Am J Respir Crit Care Med
|
2005
|
2.21
|
|
8
|
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
|
Antimicrob Agents Chemother
|
2006
|
2.18
|
|
9
|
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
|
Antimicrob Agents Chemother
|
2011
|
1.99
|
|
10
|
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
|
Am J Respir Crit Care Med
|
2012
|
1.94
|
|
11
|
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
|
Am J Respir Crit Care Med
|
2006
|
1.90
|
|
12
|
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
|
Antimicrob Agents Chemother
|
2012
|
1.83
|
|
13
|
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
|
Am J Respir Crit Care Med
|
2013
|
1.65
|
|
14
|
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
|
Antimicrob Agents Chemother
|
2012
|
1.63
|
|
15
|
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
|
Clin Infect Dis
|
2005
|
1.61
|
|
16
|
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
|
J Infect Dis
|
2009
|
1.49
|
|
17
|
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.
|
Am J Respir Crit Care Med
|
2008
|
1.47
|
|
18
|
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.
|
J Antimicrob Chemother
|
2010
|
1.40
|
|
19
|
PA-824 exhibits time-dependent activity in a murine model of tuberculosis.
|
Antimicrob Agents Chemother
|
2010
|
1.38
|
|
20
|
Therapeutic drug monitoring in the treatment of tuberculosis: an update.
|
Drugs
|
2014
|
1.34
|
|
21
|
Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
|
Clin Infect Dis
|
2009
|
1.32
|
|
22
|
Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis.
|
Pharmacotherapy
|
2002
|
1.31
|
|
23
|
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
|
Antimicrob Agents Chemother
|
2007
|
1.26
|
|
24
|
Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis.
|
Antimicrob Agents Chemother
|
2009
|
1.24
|
|
25
|
Paediatric use of second-line anti-tuberculosis agents: a review.
|
Tuberculosis (Edinb)
|
2011
|
1.19
|
|
26
|
Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
|
Antimicrob Agents Chemother
|
2010
|
1.17
|
|
27
|
The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.
|
Clin Infect Dis
|
2005
|
1.17
|
|
28
|
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
|
Bioorg Med Chem Lett
|
2008
|
1.15
|
|
29
|
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
|
Antimicrob Agents Chemother
|
2008
|
1.14
|
|
30
|
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
|
Am J Respir Crit Care Med
|
2011
|
1.13
|
|
31
|
Tuberculosis pharmacotherapy: strategies to optimize patient care.
|
Expert Opin Pharmacother
|
2009
|
1.08
|
|
32
|
Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
|
Pharmacotherapy
|
2009
|
1.06
|
|
33
|
Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis.
|
Braz J Infect Dis
|
2006
|
1.05
|
|
34
|
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
|
Antimicrob Agents Chemother
|
2013
|
1.00
|
|
35
|
Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.
|
Antimicrob Agents Chemother
|
2008
|
0.99
|
|
36
|
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
|
Antimicrob Agents Chemother
|
2012
|
0.98
|
|
37
|
Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.
|
Pharm Res
|
2009
|
0.94
|
|
38
|
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
|
Antimicrob Agents Chemother
|
2013
|
0.94
|
|
39
|
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
|
Clin Infect Dis
|
2005
|
0.94
|
|
40
|
Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.
|
Antimicrob Agents Chemother
|
2012
|
0.93
|
|
41
|
Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis.
|
Am J Trop Med Hyg
|
2009
|
0.93
|
|
42
|
Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.
|
J Antimicrob Chemother
|
2007
|
0.91
|
|
43
|
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?
|
Eur Respir J
|
2013
|
0.91
|
|
44
|
Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.
|
Infect Dis Obstet Gynecol
|
2010
|
0.89
|
|
45
|
Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
|
Antimicrob Agents Chemother
|
2003
|
0.89
|
|
46
|
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
|
Pharmacotherapy
|
2014
|
0.88
|
|
47
|
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
|
J Antimicrob Chemother
|
2012
|
0.87
|
|
48
|
Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.
|
Antimicrob Agents Chemother
|
2009
|
0.86
|
|
49
|
Editorial commentary: pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance.
|
Clin Infect Dis
|
2012
|
0.86
|
|
50
|
The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters.
|
J Antimicrob Chemother
|
2010
|
0.86
|
|
51
|
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
|
Pharm Res
|
2011
|
0.83
|
|
52
|
Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
|
Ann Pharmacother
|
2005
|
0.82
|
|
53
|
Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.
|
Antimicrob Agents Chemother
|
2013
|
0.82
|
|
54
|
The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis.
|
Clin Infect Dis
|
2004
|
0.80
|
|
55
|
Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.
|
J Antimicrob Chemother
|
2013
|
0.80
|
|
56
|
Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
|
Pharmacotherapy
|
2014
|
0.80
|
|
57
|
Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis.
|
Pharmacotherapy
|
2013
|
0.80
|
|
58
|
Antituberculosis therapy for 2012 and beyond.
|
Expert Opin Pharmacother
|
2012
|
0.80
|
|
59
|
Mycobacterium avium in pygmy rabbits (Brachylagus idahoensis): 28 cases.
|
J Zoo Wildl Med
|
2006
|
0.79
|
|
60
|
Linezolid stability in peritoneal dialysis solutions.
|
Perit Dial Int
|
2002
|
0.78
|
|
61
|
Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.
|
Antimicrob Agents Chemother
|
2011
|
0.78
|
|
62
|
Concomitant use of voriconazole and rifabutin in a patient with multiple infections.
|
Pharmacotherapy
|
2008
|
0.78
|
|
63
|
Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients.
|
Ann Pharmacother
|
2012
|
0.78
|
|
64
|
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
|
Pharmacotherapy
|
2007
|
0.78
|
|
65
|
Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis.
|
Pharmacotherapy
|
2003
|
0.78
|
|
66
|
Treatment of a tuberculous empyema with simultaneous oral and intrapleural antituberculosis drugs.
|
Can Respir J
|
2008
|
0.78
|
|
67
|
Linezolid clearance during continuous venovenous hemodiafiltration: a case report.
|
Pharmacotherapy
|
2003
|
0.77
|
|
68
|
Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.
|
Braz J Infect Dis
|
2009
|
0.77
|
|
69
|
Clearance of linezolid via continuous venovenous hemodiafiltration.
|
Am J Kidney Dis
|
2006
|
0.77
|
|
70
|
Stability of antituberculosis drugs mixed in food.
|
Clin Infect Dis
|
2007
|
0.77
|
|
71
|
Pharmacokinetic mismatch of tuberculosis drugs.
|
Antimicrob Agents Chemother
|
2012
|
0.76
|
|
72
|
Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii).
|
J Am Assoc Lab Anim Sci
|
2008
|
0.75
|
|
73
|
Reply to "Contradictory results with high-dosage rifamycin in mice and humans".
|
Antimicrob Agents Chemother
|
2013
|
0.75
|
|
74
|
Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
|
Pediatr Infect Dis J
|
2016
|
0.75
|
|
75
|
Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin.
|
Clin Infect Dis
|
2003
|
0.75
|
|
76
|
Mycobacterium tuberculosis Infection among Asian Elephants in Captivity.
|
Emerg Infect Dis
|
2017
|
0.75
|
|
77
|
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
|
Pharmacogenet Genomics
|
2017
|
0.75
|
|
78
|
Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children.
|
Pediatr Infect Dis J
|
2017
|
0.75
|
|
79
|
Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci).
|
J Zoo Wildl Med
|
2002
|
0.75
|
|
80
|
ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
|
J Zoo Wildl Med
|
2016
|
0.75
|
|
81
|
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
|
Chest
|
2002
|
0.75
|
|
82
|
Bile and gallbladder tissue concentrations of moxifloxacin in patients with acute cholecystitis.
|
Ann Pharmacother
|
2010
|
0.75
|